Literature DB >> 19747638

Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.

Emilia Jaskula1, Dorota Dlubek, Dorota Duda, Katarzyna Bogunia-Kubik, Anna Mlynarczewska, Andrzej Lange.   

Abstract

Cytomegalovirus (CMV) reactivation was analyzed in 92 recipients of allogeneic hematopoietic stem cell transplantation (HSCT) in relation to the proportion of CD4(+) lymphocytes in blood and a microsatellite polymorphism within the first intron of the interferon-gamma (IFNG) gene. CMV reactivation was found in 50% of the HSCT recipients; in 30% of these individuals, the level of CMV copies exceeded 100 per 10(5) peripheral blood (PB) cells on at least one occasion during the 100-day post-HSCT observation period. This high CMV copy level was most frequently found between 31 and 60 days post-HSCT (P = .021). Patients with > or = 100 CMV copies/10(5) cells were characterized by poorer overall survival (OS) compared with those lacking CMV copies or having < 100 CMV copies/10(5) cells (P = .04), and they suffered from severe post-HSCT complications, including acute graft-versus-host disease (aGVHD) and relapse. Thus, patients with > or = 100 CMV copies/10(5) cells were designated as having clinically significant CMV reactivation. Patients with < 10% CD4(+) lymphocytes had a higher number of CMV DNA copies than those with higher proportions of CD4(+) lymphocytes (0.62 vs 0.21, P = .001; mean +/- SEM, 4422 +/- 1667 vs 937 +/- 662 CMV copies/10(5) cells, P < .001, for the proportion of cases with reactivation and numbers of copies, respectively). Similarly, patients carrying 2 IFNG 13-CA-repeat alleles (homozygotes) had more frequent CMV reactivation (0.50 vs 0.26; P = .039) and a higher CMV load (4111 +/- 1699 vs 950+/-591 CMV copies/10(5) cells; P = .041) compared with those with other IFNG microsatellite allele constellations. Multivariate analysis demonstrated that the IFNG 13-CA-repeat homozygous genotype (odds ratio [OR] = 0.221; P = .044), a low proportion of CD4(+) lymphocytes (OR = 0.276; P = .050), and a lack of optimal (10/10 alleles) donor-recipient HLA match (OR = 15.19; P = .006) were independent risk factors for CMV reactivation with a high number of copies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19747638     DOI: 10.1016/j.bbmt.2009.06.008

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

1.  Can determination of gene polymorphism be of practical value in tailoring the treatment of HSCT patients?

Authors:  A Lange; E Jaskula
Journal:  Bone Marrow Transplant       Date:  2015-02       Impact factor: 5.483

Review 2.  Risk stratification and immunogenetic risk for infections following stem cell transplantation.

Authors:  Agnieszka Wójtowicz; Pierre-Yves Bochud
Journal:  Virulence       Date:  2016-09-09       Impact factor: 5.882

3.  Association between interferon gamma 13-CA-repeats polymorphism and metastasis of nasopharyngeal carcinoma in a population of Northern China.

Authors:  Kaifei Hao; Zhaohui Yan; Yu Shuang; Jinsong Sun; Shudong Tao; Wenyuan Fu; Lei Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 4.  Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation.

Authors:  Ajit P Limaye; Tara M Babu; Michael Boeckh
Journal:  Clin Microbiol Rev       Date:  2020-10-28       Impact factor: 26.132

5.  Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms.

Authors:  Carolina Martínez-Laperche; Ismael Buño; Miren Vallejo; Paula Muñiz; Mi Kwon; Laura Solán; Rebeca Bailén; Diego Carbonell; María Chicano; Julia Suárez-González; Pilar Catalán; José María Bellón; Juan Carlos Triviño; Nieves Dorado; David Gallardo; José Luis Díez-Martín; Natalia Ramírez
Journal:  Ann Hematol       Date:  2022-05-07       Impact factor: 4.030

6.  Anti-CMV-IgG positivity of donors is beneficial for alloHSCT recipients with respect to the better short-term immunological recovery and high level of CD4+CD25high lymphocytes.

Authors:  Emilia Jaskula; Dorota Dlubek; Agnieszka Tarnowska; Janusz Lange; Monika Mordak-Domagala; Krzysztof Suchnicki; Mariola Sedzimirska; Agata Borowik; Sylwia Mizia; Andrzej Lange
Journal:  Viruses       Date:  2015-03-23       Impact factor: 5.048

7.  First Report of CD4 Lymphopenia and Defective Neutrophil Functions in a Patient with Amebiasis Associated with CMV Reactivation and Severe Bacterial and Fungal Infections.

Authors:  Etienne Ghrenassia; Amélie Guihot; Yuan Dong; Pauline Robinet; Thierry Fontaine; Karine Lacombe; Thomas Lescot; Marie-Caroline Meyohas; Carole Elbim
Journal:  Front Microbiol       Date:  2017-02-13       Impact factor: 5.640

8.  High Monocyte Count Associated with Human Cytomegalovirus Replication In Vivo and Glucocorticoid Therapy May Be a Hallmark of Disease.

Authors:  Przemyslaw Zdziarski; Andrzej Gamian
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

Review 9.  Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients.

Authors:  Andrzej Lange; Janusz Lange; Emilia Jaskuła
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

10.  CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients.

Authors:  Emilia Jaskula; Jolanta Bochenska; Edyta Kocwin; Agnieszka Tarnowska; Andrzej Lange
Journal:  Bone Marrow Res       Date:  2012-11-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.